FDA Drug · D-1161-2022

Losartan Potassium Tablets, USP 25 mg, 90 Tablets bottles, Rx Only Marketed and Packaged By: PD-Rx Pharmaceuticals, Inc. Oklahoma City, OK 73127 Manufactured by: Vivimed Life Sciences Private Limited, Plot No. 101, 102, 107 & 108 SIDCO Pharmaceutical Complex, Alathur, Kanchipuram-603 110, Tamilnadu, India NDC 72789-163-90 UPC 3 72789 16390 1

Class II · Terminated

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Affected lots / codes — check yours against thisLots: D21C18 Exp. 09/30/22; E21A28 Exp. 09/30/22; E21C04 Exp. 09/30/22; E21D59 Exp. 09/30/22; G21B65 Exp. 09/30/22; H21A12 Exp. 09/30/22; H21D42 Exp. 09/30/22; K21D19 Exp. 10/31/22; A22A73 Exp. 10/31/22

Recalling firm: PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK
Classification: Class II (temporary or reversible harm possible)
Status: Terminated
Quantity: 1441 bottles
Distribution: Nationwide
Recall initiated: June 6, 2022
Classified: June 27, 2022
Terminated: June 17, 2024
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-1161-2022%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

See every recall for this brand: Is LOSARTAN POTASSIUM recalled? →

Check this brand across all 8 databases →